NORMAN M. KAPLAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: A massive campaign, including eight-page, heavy-paper advertisements in most medical journals, has been mounted for a new formulation of triamterene and hydrochlorothiazide, Maxzide (Lederle Laboratories, Wayne, New Jersey). The manufacturers have emphasized the improved, virtually 100% bioavailability of both ingredients in their formulation compared with that of the only other available formulation, Dyazide (SmithKline & French Co., Carolina, Puerto Rico). Dyazide has become the single largest-used diuretic product in the United States and in fact is the number one prescribed drug in volume, with 1983 sales of over $210 million.
Dyazide has 25 mg of hydrochlorothiazide, of
KAPLAN NM. Maxzide or Dyazide: A Cautionary Note. Ann Intern Med. 1985;102:717. doi: https://doi.org/10.7326/0003-4819-102-5-717_1
Download citation file:
Published: Ann Intern Med. 1985;102(5):717.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use